Engflag

Eletriptan Hydrobromide

Quick links to important sections

Eletriptan Hydrobromide

Selected form

Eletriptan Hydrobromide_ES

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eletriptan Hydrobromide

Eletriptan hydrobromide is a specialized, synthetic medicine classified within the Triptan family. It is intended as an abortive therapy to address the symptoms of acute attacks, and is generally not used for prevention.

Property Description
Active ingredient Eletriptan (as the hydrobromide salt)
Form Oral tablet (typically film-coated)
Pharmacological class Triptan; Selective serotonin 5-HT1B/1D receptor agonist
General purpose Abortive therapy (to stop an episode in progress)
Origin Synthetic molecule (second-generation Triptan)

What Type of Medicine is Eletriptan Hydrobromide?

Eletriptan hydrobromide is a prescription-only, synthetic compound classified as a Triptan, which is a high-level pharmacological class of medicines known as selective serotonin receptor agonists. It is considered a second-generation Triptan. It is classified as a Serotonin 1b and 1d Receptor Agonist. This specific targeting is a defining characteristic of this compound compared to non-selective analgesics.

Composition and Physical Form

The core active ingredient is Eletriptan, combined with the hydrobromide salt to ensure chemical stability. This single-active-ingredient molecule is synthetic in origin, developed in a laboratory setting. The medicine is supplied exclusively as an oral tablet for administration by mouth. Eletriptan is distinguished among the Triptans by its relatively high lipophilicity, a characteristic that influences its absorption and ability to access its central sites of action.

General Purpose and Mechanism Summary

Eletriptan hydrobromide serves as an abortive therapy, meaning its general purpose is to be taken after symptoms have begun to help interrupt the acute process, such as during the onset of a typical migraine episode. Its therapeutic action is achieved by two primary principles: causing cranial vessel constriction and the inhibition of pro-inflammatory nerve signals. The vasoconstriction effect helps to normalize blood flow, which is correlated with the relief of symptoms.

What side effects are possible with Eletriptan Hydrobromide?

Possible Side Effects and Safety Information

Adverse reactions to Eletriptan Hydrobromide are officially classified by frequency and grouped according to the physiological system affected, as documented in regulatory prescribing information (e.g., FDA and EMA labels). The profile emphasizes both common transient effects and mandatory warnings concerning rare, serious events related to its vasoconstrictive nature.

Regulatory Classification of Adverse Reactions

Side effects are most frequently reported within the Nervous System (dizziness, somnolence, paresthesia), Gastrointestinal Disorders (nausea, dry mouth), and General Disorders (asthenia, sensations of pressure or tightness). These are often classified as Common, affecting 1 to 10 people out of 100.

Frequency Category Representative Reactions
Common Dizziness, Somnolence, Nausea, Asthenia, Dry mouth, Paresthesia, Chest discomfort.
Uncommon Tachycardia, Palpitations, Vertigo, Tremor, Dyspnoea.

Serious Adverse Reactions and Safety Constraints

Official labels contain prominent warnings regarding serious adverse reactions, which include the potential for Myocardial Ischemia, Myocardial Infarction, Coronary Artery Vasospasm, and Cerebrovascular Events (stroke). The risk of Serotonin Syndrome is also documented, particularly with co-administration of other serotonergic medicines.

Regulatory documents impose specific restrictions. The medicine is contraindicated in patients with pre-existing conditions such as ischemic heart disease, uncontrolled hypertension, prior stroke or transient ischemic attack, and severe hepatic impairment. Furthermore, the development of Medication Overuse Headache (MOH) is officially documented as a safety pattern associated with frequent or prolonged use. Safety and efficacy are not established for pediatric patients, and the medicine is generally not recommended for use in older adults (over 65 years).

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help

Overdose Scope

Documented overdose presentations: Overdose may lead to an exaggeration of known effects, including hypertension and CNS manifestations such as somnolence and dizziness.

Physiological systems affected (as stated in label): Primary concerns involve the Cardiovascular System (potential for ischemia/infarction) and the Central Nervous System (CNS) (risk of Serotonin Syndrome).

Dose-related or exposure-related factors (if applicable): The risk of Serotonin Syndrome is a specific concern when used with other serotonergic agents.

Population-specific overdose notes (if applicable): Caution is advised when treating patients with renal impairment due to the potential for amplified blood pressure effects.

Emergency-response statements (as written in official documents)

Seek emergency medical attention or contact the Poison Control Center immediately upon suspicion of an overdose. If the individual collapses, has a seizure, or experiences trouble breathing, call emergency services.

When immediate medical help is required (label-derived phrasing only): Urgent medical attention is mandated for symptoms suggestive of Myocardial Infarction, Cerebrovascular Events (stroke), or Serotonin Syndrome (e.g., agitation, sudden severe pain, or slurred speech).

Overdose classifications (high-level)

Severity classification (as defined in official documents): Overdose can lead to severe or life-threatening outcomes.

Regulatory basis (EMA / FDA / etc.): This information is derived from official labeling, such as the FDA Prescribing Information.

Overdose-context constraints (as defined in official documents): Prolonged monitoring for at least 20 hours or longer is necessary due to the drug’s elimination half-life. No specific antidote is known; management is symptomatic and supportive.

Resulting overdose structure

Official overdose statements:

  • Overdose is characterized by severe cardiovascular effects and CNS manifestations, including hypertension and the potential for Serotonin Syndrome.
  • Seek emergency medical attention immediately upon suspicion of overdose or onset of severe symptoms.
  • Treatment is strictly symptomatic and supportive, and no specific antidote is known.

Connection to the overall overdose profile (2–4 sentences):

Regulatory documents define the Eletriptan overdose profile based on the risk of severe cardiovascular and neurological toxicity resulting from the drug's activity. This potential for serious, life-threatening events dictates the clear regulatory instruction that individuals must seek emergency medical help immediately for any suspected overdose. The required management includes prolonged monitoring of the cardiorespiratory system.

Therapeutic Uses of Eletriptan Hydrobromide

What Eletriptan Hydrobromide Treats: Main Uses and Benefits

Eletriptan hydrobromide is an oral prescription medication used for the acute treatment of migraine headaches in adults, which may or may not include an accompanying aura. This triptan belongs to the class of medicines known as triptans, and its role is not in prevention, but to help resolve the headache phase when taken during a headache phase.

The medication is indicated for addressing the pain associated with a diagnosed migraine. It is associated with the relief of accompanying migraine symptoms, such as nausea, vomiting, and sensitivities to light (photophobia) and sound (phonophobia).

The primary therapeutic purpose is symptom relief during a migraine attack. It addresses both the headache pain and the commonly associated symptoms. The use of the medicine is specific to treating diagnosed migraine, not other types of headaches.

Quick Fact: Relief for Associated Migraine Symptoms

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eletriptan Hydrobromide is officially indicated for the acute treatment of migraine with or without aura in adults who fall within the approved age range, typically 18 to 65 years. Eligibility is strictly defined by regulatory authorities based on pre-existing health conditions and age.

Populations for Whom Use is Contraindicated

The medicine must not be used by patients with:

  • Ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, documented silent ischemia).
  • Cerebrovascular events (history of stroke or transient ischemic attack [TIA]).
  • Specific Migraine Types: Hemiplegic or basilar migraine.
  • Vascular Disease: Peripheral vascular disease or ischemic bowel disease.
  • Hypertension: Uncontrolled high blood pressure.
  • Severe Organ Impairment: Severe hepatic impairment.

Age- and Condition-Based Restrictions

Population Category Regulatory Status Official Constraint
Pediatric (Under 18) Not Recommended Safety and efficacy are not established for this age group.
Geriatric (Over 65) Not Recommended Limited clinical data; potential for a greater increase in blood pressure.
Pregnancy Category C (FDA) Use only if the potential benefit justifies the potential risk.
Lactation Use with Caution Eletriptan is excreted into human milk; avoiding breastfeeding for 24 hours post-treatment can minimize infant exposure.

Patients with multiple cardiovascular risk factors must undergo a thorough cardiovascular evaluation before use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Eletriptan Hydrobromide carries documented interaction risks primarily related to its metabolism and pharmacodynamic effects, as outlined in official regulatory information.

1. Contraindicated Combinations

Due to the risk of cumulative effects, eletriptan must not be used concurrently with:

  • Other 5-HT1 Agonists (Triptans): This includes all other medications in the triptan class.
  • Ergotamine-Containing or Ergot-type Medications: Such as ergotamine, dihydroergotamine, and methysergide.
  • Potent CYP3A4 Inhibitors: Specific agents that significantly increase eletriptan exposure, including ketoconazole, itraconazole, clarithromycin, and ritonavir.

2. Timing Separation Requirements

  • A separation of at least 72 hours is required between taking eletriptan and the listed potent CYP3A4 inhibitors.
  • A separation of 24 hours must be maintained between taking eletriptan and any other triptan or ergot-type medication.

3. Pharmacodynamic Interactions

  • SSRIs and SNRIs: Concomitant use with Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) may increase the official risk of Serotonin Syndrome.

4. Exposure Modification

Eletriptan is primarily metabolized by the enzyme CYP3A4. Medications like verapamil and fluconazole are documented to cause a clinically significant increase in eletriptan plasma concentrations (AUC and Cmax).

Mechanism of Action

Eletriptan hydrobromide is a selective serotonin receptor agonist that functions by engaging specific receptors located in the cranial vasculature and peripheral nerve endings. Its activity involves the modulation of the serotonin system, initiating a cascade of effects that modify local pathway activity.

5-HT1B and 5-HT1D Receptor Agonism

Eletriptan acts as an agonist at the 5-HT1B and 5-HT1D serotonin receptor subtypes. Activation of 5- HT1B receptors occurs on the smooth muscle of intracranial blood vessels, and activation of 5- HT1D receptors occurs on presynaptic trigeminal nerve endings. This engagement initiates signaling sequences that modulate vessel diameter and nerve excitability.

Vasoconstrictive Effect

Activation of 5- HT1B receptors causes vasoconstriction of certain arteries in the dura mater, thereby reducing local vessel diameter and modifying fluid dynamics in the targeted vasculature.

Inhibition of Mediator Release

Agonism at 5- HT1D receptors on the nerve terminals of the trigeminal nervous system inhibits the release of neuropeptides, including calcitonin gene-related peptide (CGRP). This molecular modification inhibits the propagation of signaling sequences mediated by these transmitters.

Dosage and Administration Information

How to Use Eletriptan Hydrobromide

Eletriptan hydrobromide is administered exclusively as an oral tablet and is intended only for the acute treatment of migraine headaches, not for preventive therapy. The tablets may be taken with or without food and should be swallowed whole with water.

Administration is initiated only after the onset of the headache phase of the migraine, and the medication is not indicated for use during the preceding aura phase.

Official Dosing and Frequency

The standard initial single dose for adults is 20 mg or 40 mg Eletriptan base. The maximum single dose is 40 mg, and the total dose in any 24-hour period must not exceed 80 mg.

Dosing Rule Official Labeled Instruction
Timing for Second Dose A second dose may be taken if the migraine returns after initial improvement.
Minimum Interval At least 2 hours must pass between the first and second dose.
Non-Response Rule If the first dose provided no response (no improvement), a second dose should not be taken for that same attack.

Population and Contextual Restrictions

Specific limitations on administration are established for certain patient groups. Use is not recommended for individuals over 65 years of age or for patients under 18, as safety and effectiveness have not been systematically evaluated in these populations. For patients with mild to moderate renal impairment, the maximum dose in 24 hours should not exceed 40 mg. Furthermore, there is a 72-hour mandatory waiting period after the cessation of certain potent CYP3A4 inhibitors before Eletriptan may be taken. These instructions define the standardized administration protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Eletriptan Hydrobromide

Research exploring Eletriptan hydrobromide was studied for understanding its use as an acute, episodic treatment for migraine headaches. The clinical evidence was developed using randomized, controlled trials (RCTs). These short-term studies are designed to compare the effects of the medicine against an inactive substance (placebo) under specific, controlled conditions.

Evidence for Acute Treatment of Migraine Headache

Studies were conducted on adults with diagnosed migraine and measured outcomes related to physical discomfort (headache pain) at the two-hour mark after dosing. Research examined whether patients achieved an absence of pain or a reduction of pain severity to a mild level. Research also examined secondary endpoints related to patient-reported outcomes describing perceived discomfort, such as freedom from nausea or light sensitivity.

Sustained Response, Recurrence, and Multi-Attack Studies

Studies monitored outcomes reflecting episodic or acute changes, tracking how long the measured change in headache status was maintained, and tracked the rate of headache recurrence over 24 hours. While the core evidence focuses on treating a single attack, some studies explored multiple migraine episodes over longer durations.

Evidence in Specific Patient Populations

Evidence for women treating menstrual-related migraine relies on pooled analyses of existing trial data, and these subgroup findings are uncertain due to the secondary nature of the analysis. For specific populations, limited data are available for older adults (over 65 years). Research exploring the medicine's use has not been established for pediatric patients (children and adolescents), and research reflects these gaps.

What Remains Uncertain About the Research Evidence

There is limited information for long-term outcomes regarding continuous or frequent use. Research provides limited information regarding the treatment of an average of more than three migraine attacks in a 30-day period. Additionally, the medicine was not the subject of research for the prevention of migraine or the acute treatment of other severe headache types.

How should Eletriptan Hydrobromide be stored and disposed of?

How to Store and Dispose of Eletriptan Hydrobromide

Eletriptan hydrobromide must be stored at Controlled Room Temperature, which is defined by regulatory labeling as a range of 20°C to 25°C (68°F to 77°F). Storage excursions are permitted between 15°C and 30°C.

Protection from moisture is required; if the medicine is dispensed in a bottle, the container must be kept tightly closed. If supplied in blister packs, no special storage conditions are noted beyond the temperature requirements.

Handling and Disposal

The medicine must be stored out of the sight and reach of children as a mandatory safety requirement.

Disposal of unused or expired tablets must comply with local, state, and federal disposal regulations. To protect the environment, the medication should not be flushed down the toilet or poured into drains, and should be returned to a pharmacy take-back program where available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagUSA

Equivalent of Eletriptan Hydrobromide found in:

A-Z Index: